WINDLAS NSI Week ended 07 Aug 2026

Weekly Investor Report

Windlas Biotech Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 882.8 INR
2.9% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 8.4% above the Trend Line and sits at 46.3% of its 52-week range. The latest completed week returned 2.9%, after a 7.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 57 out of 100
Latest Close 882.8 INR 7 Aug 2026
1W Return 2.9% latest completed week
4W Return 7.2% short-term follow-through
12W Return 13.3% quarterly tape
Trend Breadth 34.6% 18 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 11-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 43.72% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.9% Latest completed week; four-week move 7.2%. Indicator stack 57/72 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.72% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 25 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 8.4% above the Trend Line and sits at 46.3% of its 52-week range. The latest completed week returned 2.9%, after a 7.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5612-week average 0.40

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.56Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 7.2% over four weeks, 13.3% over 12 weeks, and -4.0% over one year. The current trend has remained active for 11 consecutive weeks.

Performance by holding period

1W2.9%
4W7.2%
12W13.3%
26W3.4%
52W-4.0%
Active trend streak11 weeks
Active weeks in one year18
Trend breadth34.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.09Latest activity-pressure read.
Pressure change23.1%Four-week change in activity pressure.
Leadership5.15Latest relative-leadership reading.
RS change582.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 88%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength53/100Blend of value, momentum, and quality. Underlying universe rank 48; rank 1 is best.
Value65/100Relative valuation strength. Underlying universe rank 36; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum34/100Medium-term price momentum. Underlying universe rank 67; rank 1 is best.
Growth66/100Revenue and earnings growth. Underlying universe rank 35; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework40/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
27.4x
Price divided by trailing earnings.
Price / sales
2.0x
Market value relative to trailing revenue.
EV / EBITDA
15.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
38.4%
Gross profit retained from each unit of revenue.
Operating margin
8.2%
Operating profit retained from revenue.
Free-cash-flow margin
4.1%
Free cash flow generated from revenue.
Return on invested capital
9.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
18.9%
Latest one-year revenue growth.
EPS growth
8.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
133.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.7%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 25 relevant articles.

6 positive · 19 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-19.6%Distance below the 52-week high.
13-week volatility3.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+8.2%Week of 17 Apr.
Worst week-5.8%Week of 13 Feb.
Latest week+2.9%Week of 7 Aug.

Shape of recent returns

Strong gains5
Modest gains7
Flat weeks0
Modest losses11
Sharp losses3
Recent vol3.2%13-week weekly-return volatility.
Base vol4.3%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew3.8% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape55/100

Trend, activity pressure, participation, and risk combine to a 55/100 tape read.

 Indicator analysis77/100

Latest 12-week confirmation: trend 11/12, activity pressure 12/12, relative leadership 9/12.

Activity pressure 0.56; No reversal markers Next-Week ExpectancyNegative 43.72%

Next-week expectancy is negative with a 43.72% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors48/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 64; Small Cap Core rank 42 SVQF40/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 941.0 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 25 relevant articles.

Windlas Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026882.8 INR2.9%814.2 INR765.6 INR1.095.15154.1KOn
31 Jul 2026857.7 INR-0.0%809.8 INR762.4 INR0.902.83116.9KOn
24 Jul 2026858.0 INR1.6%807.5 INR758.8 INR0.995.28172.1KOn
17 Jul 2026844.2 INR2.5%805.5 INR755.4 INR1.030.98335.0KOn
10 Jul 2026823.7 INR-4.8%803.3 INR752.1 INR0.89-1.07216.3KOn
3 Jul 2026865.4 INR1.5%801.9 INR748.9 INR0.873.5962.1KOn
26 Jun 2026852.6 INR5.3%798.7 INR745.4 INR0.732.990On
19 Jun 2026809.9 INR-1.0%796.4 INR741.9 INR0.82-1.9444.8KOn
12 Jun 2026818.1 INR0.5%795.9 INR738.6 INR0.860.6265.9KOn
5 Jun 2026814.2 INR-2.3%796.0 INR735.2 INR0.801.0774.2KOn
29 May 2026833.1 INR5.5%797.8 INR731.7 INR0.812.54468.2KOn
22 May 2026790.0 INR1.4%801.6 INR728.1 INR0.79-3.54414.7KOff
15 May 2026779.4 INR-5.3%806.2 INR724.8 INR1.00-4.71275.5KOff
8 May 2026822.8 INR-3.4%811.1 INR721.5 INR1.29-1.89174.5KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context